Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Osimertinib, an irreversible EGFR-TKI, in relapsed EGFR-mutated non-small cell lung cancer patients previously treated with an EGFR-TKI, coupled to extensive translational studies

Trial Profile

Osimertinib, an irreversible EGFR-TKI, in relapsed EGFR-mutated non-small cell lung cancer patients previously treated with an EGFR-TKI, coupled to extensive translational studies

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Osimertinib (Primary)
  • Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms TREM
  • Most Recent Events

    • 27 Mar 2023 Planned End Date changed from 1 Dec 2021 to 1 Jun 2023.
    • 27 Mar 2023 Planned primary completion date changed from 1 Jan 2021 to 1 Jun 2023.
    • 09 Aug 2022 Plasma samples of 20 patients from this study was used to analyze exosomal RNAs, presented at the 2022 World Conference on Lung Cancer
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top